Neurolixis’ new drug targets serotonin 1A receptors, showing promise in preclinical studies for Fragile X syndrome, funded by a FRAXA grant for future clinical trials.
Read more
FRAXA Research Foundation – Finding a Cure for Fragile X Syndrome
Accelerating Fragile X Research for Effective Treatments